Neurocrine Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1994
Revenue	1,887	1,489	1,134	1,046	788.1	Upgrade
Revenue Growth (YoY)	26.76%	31.34%	8.38%	32.71%	74.67%	Upgrade
Cost of Revenue	39.7	23.2	14.3	10.1	7.4	Upgrade
Gross Profit	1,847	1,466	1,119	1,036	780.7	Upgrade
Selling, General & Admin	887.6	752.7	583.3	433.3	354.1	Upgrade
Research & Development	565	463.8	328.1	275	200	Upgrade
Other Operating Expenses	143.9	0	105.3	164.5	154.3	Upgrade
Operating Expenses	1,597	1,217	1,017	872.8	708.4	Upgrade
Operating Income	250.9	249	102.5	163	72.3	Upgrade
Interest Expense / Income	4.6	7.1	25.8	32.8	32	Upgrade
Other Expense / Income	-85.8	28	-24.7	23.5	-6.2	Upgrade
Pretax Income	332.1	213.9	101.4	106.7	46.5	Upgrade
Income Tax	82.4	59.4	11.8	-300.6	9.5	Upgrade
Net Income	249.7	154.5	89.6	407.3	37	Upgrade
Net Income Growth	61.62%	72.43%	-78.00%	1000.81%	75.36%	Upgrade
Shares Outstanding (Basic)	98	96	95	93	92	Upgrade
Shares Outstanding (Diluted)	101	99	98	98	96	Upgrade
Shares Change	2.12%	1.02%	0.10%	2.19%	0.31%	Upgrade
EPS (Basic)	2.56	1.61	0.95	4.38	0.40	Upgrade
EPS (Diluted)	2.47	1.56	0.92	4.16	0.39	Upgrade
EPS Growth	58.33%	69.57%	-77.88%	966.67%	77.27%	Upgrade
Free Cash Flow	361.6	322.9	233.1	217.6	132.3	Upgrade
Free Cash Flow Per Share	3.70	3.37	2.46	2.34	1.44	Upgrade
Gross Margin	97.90%	98.44%	98.74%	99.03%	99.06%	Upgrade
Operating Margin	13.30%	16.73%	9.04%	15.58%	9.17%	Upgrade
Profit Margin	13.23%	10.38%	7.90%	38.94%	4.69%	Upgrade
Free Cash Flow Margin	19.16%	21.69%	20.56%	20.81%	16.79%	Upgrade
Effective Tax Rate	24.81%	27.77%	11.64%	-281.72%	20.43%	Upgrade
EBITDA	358	236.6	138.1	148.1	85.9	Upgrade
EBITDA Margin	18.97%	15.89%	12.18%	14.16%	10.90%	Upgrade
Depreciation & Amortization	21.3	15.6	10.9	8.6	7.4	Upgrade
EBIT	336.7	221	127.2	139.5	78.5	Upgrade
EBIT Margin	17.84%	14.85%	11.22%	13.34%	9.96%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).